Literature DB >> 32551018

Discovery of Novel Nonpeptidic PAR2 Ligands.

Ilona Klösel1, Maximilian F Schmidt1, Jonas Kaindl1, Harald Hübner1, Dorothee Weikert1, Peter Gmeiner1.   

Abstract

Proteinase-activated receptor 2 (PAR2) is a class A G protein-coupled receptor whose activation has been associated with inflammatory diseases and cancer, thus representing a valuable therapeutic target. Pathophysiological roles of PAR2 are often characterized using peptidic PAR2 agonists. Peptidic ligands are frequently unstable in vivo and show poor bioavailability, and only a few approaches toward drug-like nonpeptidic PAR2 ligands have been described. The herein-described ligand 5a (IK187) is a nonpeptidic PAR2 agonist with submicromolar potency in a functional assay reflecting G protein activation. The ligand also showed substantial β-arrestin recruitment. The development of the compound was guided by the crystal structure of PAR2, when the C-terminal end of peptidic agonists was replaced by a small molecule based on a disubstituted phenylene scaffold. IK187 shows preferable metabolic stability and may serve as a lead compound for the development of nonpeptidic drugs addressing PAR2.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32551018      PMCID: PMC7294704          DOI: 10.1021/acsmedchemlett.0c00154

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  39 in total

1.  An Efficient Metadynamics-Based Protocol To Model the Binding Affinity and the Transition State Ensemble of G-Protein-Coupled Receptor Ligands.

Authors:  Noureldin Saleh; Passainte Ibrahim; Giorgio Saladino; Francesco Luigi Gervasio; Timothy Clark
Journal:  J Chem Inf Model       Date:  2017-05-08       Impact factor: 4.956

Review 2.  Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations.

Authors:  Yoonji Lee; Shaherin Basith; Sun Choi
Journal:  J Med Chem       Date:  2017-07-21       Impact factor: 7.446

3.  Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells.

Authors:  Nithiananthan Asokananthan; Peter T Graham; Joshua Fink; Darryl A Knight; Anthony J Bakker; Andrew S McWilliam; Philip J Thompson; Geoffrey A Stewart
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

Review 4.  Impact of GPCR Structures on Drug Discovery.

Authors:  Miles Congreve; Chris de Graaf; Nigel A Swain; Christopher G Tate
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

5.  Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors.

Authors:  Hyunjae Chung; Magda Hamza; Katerina Oikonomopoulou; Valérie Gratio; Mahmoud Saifeddine; G Duke Virca; Eleftherios P Diamandis; Morley D Hollenberg; Dalila Darmoul
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

6.  The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo.

Authors:  Andrea N Flynn; Dipti V Tillu; Marina N Asiedu; Justin Hoffman; Josef Vagner; Theodore J Price; Scott Boitano
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

7.  Identification and characterization of novel small-molecule protease-activated receptor 2 agonists.

Authors:  Luis R Gardell; Jian-Nong Ma; Jimmi Gerner Seitzberg; Anne E Knapp; Hans H Schiffer; Ali Tabatabaei; Christopher N Davis; Michelle Owens; Bryan Clemons; Kenneth K Wong; Birgitte Lund; Norman R Nash; Yan Gao; Jelveh Lameh; Kara Schmelzer; Roger Olsson; Ethan S Burstein
Journal:  J Pharmacol Exp Ther       Date:  2008-09-03       Impact factor: 4.030

8.  Essential role for proteinase-activated receptor-2 in arthritis.

Authors:  William R Ferrell; John C Lockhart; Elizabeth B Kelso; Lynette Dunning; Robin Plevin; Stephen E Meek; Andrew J H Smith; Gary D Hunter; John S McLean; Frances McGarry; Robert Ramage; Lu Jiang; Toru Kanke; Junichi Kawagoe
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

9.  Development and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tethering.

Authors:  Scott Boitano; Justin Hoffman; Dipti V Tillu; Marina N Asiedu; Zhenyu Zhang; Cara L Sherwood; Yan Wang; Xinzhong Dong; Theodore J Price; Josef Vagner
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

10.  Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists.

Authors:  Hongtao Liu; Josefa Hofmann; Inbar Fish; Benjamin Schaake; Katrin Eitel; Amelie Bartuschat; Jonas Kaindl; Hannelore Rampp; Ashutosh Banerjee; Harald Hübner; Mary J Clark; Sandra G Vincent; John T Fisher; Markus R Heinrich; Kunio Hirata; Xiangyu Liu; Roger K Sunahara; Brian K Shoichet; Brian K Kobilka; Peter Gmeiner
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-07       Impact factor: 11.205

View more
  1 in total

1.  The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects.

Authors:  Charlotte Avet; Claudio Sturino; Sébastien Grastilleur; Christian Le Gouill; Meriem Semache; Florence Gross; Louis Gendron; Youssef Bennani; Joseph A Mancini; Camil E Sayegh; Michel Bouvier
Journal:  Commun Biol       Date:  2020-11-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.